Journal
DERMATOLOGY
Volume 203, Issue 1, Pages 57-59Publisher
KARGER
DOI: 10.1159/000051705
Keywords
adverse drug reaction; tyrosine kinase inhibitor; leukemia
Categories
Ask authors/readers for more resources
The tyrosine kinase inhibitor STI571 is a novel promising class of anticancer drugs. We report a case of cutaneous adverse reactions to STI571 in a young woman with blast crisis of chronic myeloid leukemia. She had first typical acute generalized exanthematous pustulosis mimicking mercury rash and then urticarial eruption. We suggest that cell pathways mediated by some tyrosine kinases might be involved in the pathogenesis of these skin eruptions. Copyright (C) 2001 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available